KyungDong Pharm home
Prescription Medicines

Gaspren Tab.

Product Category
Functional indigestion treatment
Active Ingredients
Mosapride citrate
Appearance
White, oblong, film-coated tablets with dividing lines.
Reimbursement Code
648102540
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Mosapride citrate dihydrate (JP) ----- 5.29mg (5mg as Mosapride citrate anhydrous)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: titanium oxide, citric acid hydrate, magnesium stearate, low-substituted hydroxypropyl cellulose, crospovidone, povidone, polyethylene glycol 6000, hypromellose 2910

2. Effectiveness
Digestive symptoms due to functional dyspepsia (heartburn, nausea, vomiting)

3. Dosage and dosage
Adults: Mosapride citrate anhydrous, 15 mg divided into 3 times per day, administered orally before or after meals.

4. Precautions for use
1. Do not administer to the following patients.
Because this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Adverse reactions
Adverse reactions occurred in 40 of 998 cases (4.0%). Major adverse reactions include diarrhea and loose stools (1.8%), dry mouth (0.5%), and malaise (0.3%).
Abnormal fluctuations were seen in clinical examination values in 30 of 792 cases (3.8%). Main contents include increased eosinophilia (1.1%), increased neutral fat (1.0%), and increased AST, ALT, ALP, and γ-GTP (0.4% each).
1) Serious adverse reactions
Fulminant hepatitis, liver dysfunction, and jaundice (less than 0.1% each): Severe liver dysfunction and jaundice accompanied by fulminant hepatitis, significant elevations of AST, ALT, and γ-GTP may occur, and in some cases, death may occur. Therefore, observe thoroughly, and if abnormalities are confirmed, immediately stop administration and take appropriate measures.
2) Other adverse reactions
(1) Hypersensitivity reaction: rash, hives, sometimes swelling
(2) Blood system: Occasionally increased eosinophils, decreased white blood cells
(3) Digestive system: Abdominal bloating, oral paralysis (including tongue and lips), occasional diarrhea, loose stools, dry mouth, abdominal pain, nausea, vomiting, and dysgeusia.
(4) Liver: Occasionally, ALP rises, bilirubin rises, and ALT rises. Rarely, elevations of AST and γ-GTP
(5) Circulatory system: Sometimes palpitations
(6) Mental nervous system: Occasional dizziness, staggering, headache
(7) Others: Tremor, occasional malaise, increase in neutral fat
3) Domestic post-marketing survey results
As a result of a post-marketing use results survey conducted on 745 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 1.9% (14 cases/745 cases) regardless of causal relationship, and among these, 1.3% (10 cases/745 cases) were found to have a causal relationship with this drug. Regardless of causal relationship, adverse reactions included abdominal pain, diarrhea in 4 cases, loose stools in 3 cases, nausea in 2 cases, abdominal distension, indigestion, excessive milk secretion, malaise, and rash in 1 case each. Among these, one case each of indigestion and excessive milk secretion were reported as new adverse reactions that did not appear in pre-market clinical trials.
4) Post-marketing surveillance results in foreign countries
As a result of the post-marketing use results survey conducted in Japan, adverse reactions occurred in 74 out of 3,014 cases (2.5%). Major adverse reactions include diarrhea and loose stools (0.8%), abdominal pain (0.4%), and dry mouth (0.3%).
5) As a result of analyzing domestic voluntary adverse event reporting data (1989-2013), the adverse events reported in statistically significantly higher numbers compared to adverse events occurring in other drugs for which adverse events were reported were as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
· Drowsiness

3. General precautions
If no improvement in digestive symptoms is seen even after administration for a certain period of time (usually 2 weeks), do not administer for a long period of time.

4. Interaction
Due to the relationship between the digestive tract motility promoting effect of this drug and cholinergic nerves, the action of this drug may be reduced when administered in combination with anticholinergics (atropine sulfate, butylscopolamine bromide, etc.), so caution should be exercised when using it in combination, such as leaving a gap between doses.

5. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) Since transfer to breast milk has been reported in animal experiments, administration should be avoided during lactation, and lactation should be discontinued if unavoidable circumstances arise.

6. Administration to children
Safety for children, etc. has not been established (there is no experience of use).

7. Administration to elderly people
In general, in elderly patients, physiological functions such as renal function and liver function are reduced, so administer with caution while observing the patient's condition, and if adverse reactions occur, take appropriate measures such as reducing the dose (e.g., 7.5 mg per day).

8. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

9. Other
In a test in which 100 to 300 times the usual clinical dose (30 to 100 mg/kg/day) was orally administered to rodents for a long period of time (rats for 104 weeks, mice for 92 weeks), an increase in the incidence of tumors (hepatocellular adenoma and thyroid follicular tumor) was observed.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Gaspren Tab.Gaspren tablets (precautions for use)2015.04.02HWPPermission change instructions_Precautions for use_Mosaprid_3.h
1Gaspren Tab.Gaspren tablets (efficacy, dosage, directions for use...2012.12.31HWPGaspren Tablet_Permission Change Order.hwp